BIA BIOFINANCE AND BIOINNOVATE EUROPE 2008
MONDAY 9 JUNE, ROYAL COLLEGE OF PHYCIANS, LONDON
Event Founder Sponsor:
09.00
BIA Welcome
Dr Clive Dix, Chairman, BIA
NovaQuest Welcome
Ian Birks, Vice President Alliance Management, NovaQuest
09.15
Keynote Presentation
Complementing challenges in a tough industry: The importance of external innovation to the pharma industry and the key role of strategic partnerships between pharma and biotech
Speaker: Dr Patrick Vallance, Senior Vice President, Drug Discovery, GlaxoSmithKline
09.45
Opening Panel: A view of the sector in 2008 and beyond
Panel of industry experts discuss their thoughts on the shape and health of the sector in 2008 and looking forward to 2009/2010
Session Chair: Andrew Jack, Pharmaceuticals Correspondent, The Financial Times
Speakers: Dennis Purcell, Senior Managing Director, Aisling Capital Ian Birks, Vice President Alliance Management, NovaQuest Dr Dave Tapolczay, Chief Executive, MRC Technology (MRCT) Iain Wilcock, Healthcare Investment Director, NESTA William Powlett-Smith, UK Biotechnology leader, Ernst & Young
10.30
The impact of major licensing and M&A deals on share price and share trade volumes
Different perspectives on the value of a major deal: the two parties involved, analysts and fund managers
Session sponsored by:
Session chair: Gary Howes. Partner, Intellectual Property, and Head of Health Science Group, Fasken Martineau Stringer Saul LLP
Speakers: Nick Adams, Director of Business Development, Antisoma Nick Woolf, Executive Director, Senior Vice President, Corporate Strategy, Oxford BioMedica Ian Scoular, Director of Business Development, Protherics PLC Dr Daniel Mahony, Fund Manager, Polar Capital Partners Analyst TBC
11.15
Coffee Break & Networking
11.40
Alternative Business Models - The Portfolio Approach
Speakers: Dr Sam Williams, Chief Executive Officer, Modern Biosciences plc Dr Kevin Johnson, Chief Executive Officer, PanGenetics Silvano Spinelli, Founder and CEO, EOS (Ethical Oncology Science)
12.30
VC Wish List for 2008 and beyond
The current state of the venture financing market and a brief roundup of the deals from 2007/early 2008 and what are VC's looking to invest in during the next 12 months
Speakers: Gordon Duncan, Founder. IPEEX Dr Allan Marchington, Partner, Apposite Capital LLP David Baynes, CEO, Biofusion PLC Kate Bingham, Partner, SV Life Sciences LLP Dr Regina Hodits, Partner, Atlas Venture
13.15
Lunch & Networking
BioInnovate Track
BioFinance Track
14.15
Workshop:
Focus on Investment agreements and listing on AIM
Facilitated by:
Workshop:
Maximising the value of your Intellectual Property
Facilitated by:
Perspectives from other European markets
An overview of the top performers and what can be learnt from these markets with a focus on Denmark and Switzerland.
Speakers: Dr Claus Moller, Chief Operating Officer, Genmab Dr Alice Huxley, CEO, Speedel
15.00
Workshop:
Communication and press releases
Facilitated by:
Workshop:
How to write a business plan: The good, the bad and the ugly
Facilitated by:
Product-Based Financing
Why different organisations use this method of financing: Not for profit, early stage biotechs and organisations with mature pipelines
Session sponsored by:
Session chair:Dr Ken Macleod, Principal, Paul Capital Advisors UK Ltd
Speaker: Dr Steven Powell, Chief Executive Officer, Plethora Solutions Kristian Wiggert, Managing Partner, Morrison & Foerster
15.45
Afternoon Tea & Networking
16.15
Accelerating Innovation via licensing
Companies share their models, experiences and recommendations
Session supported by:
Session chair: Jennifer Pierce, Co-Chair, Licensing Executives Society
Speakers: Martin Gouldstone, Director of Business Development, Sareum Ltd Christine Soden, Chief Financial Officer, BTG Dr Shelagh Wilson, Vice President, Biology, Centre of Excellence for External Drug Discovery (CEEDD), GlaxoSmithKline Dr Will West, Chief Executive, CellCentric
Debt Financing
Perspectives from a balance sheet lender and a specialist venture debt provider
Session sponsored by:
Session chair: John Aston, CFO, Astex Therapeutics
Speakers: Richard Honey, ETV Capital Marcus O'Neill, GE Healthcare Financial Services Brad Hoy, Chief Financial Officer, Plethora Solutions Holdings plc
17.00
Focus on grants
What's available and how to apply for government grants, charity grants and research council grants
Session supported by:
Session chair: Dr Tony Bradshaw, Director, bioProcessUK
Speakers: Dr Richard Seabrook, Head of Business Development, Technology Transfer, Wellcome Trust Richard Hancock, Director, GHB Brussels Dr Zahid Latif, Lead Technologist - Bioscience and Healthcare, Technology Strategy Board Phytopharm, representative TBC
New kids on the block
A review of new funds from the USA, Europe and the Far East
Speaker: Dr David Parry, CEO, SEHTA Gareth Powell, Fund Manager, Polar Capital Partners Andrew Garai, Managing Partner, Trafalgar Capital Advisors
17.45
Evening Networking Reception
Kindly sponsored by:
Keynote speakers: Glen Giovannetti, Global Biotechnology Leader, Ernst & Young Ian Oliver, Senior Manager, Ernst & Young
